Status:
COMPLETED
68Ga-DOTA-hLAG-3 PET Imaging of LAG-3 Expression in Cancers
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Conditions:
PET/CT
hLAG-3
Eligibility:
All Genders
18-90 years
Brief Summary
To evaluate the potential usefulness of 68Ga-DOTA-hLAG-3 positron emission tomography/computed tomography (PET/CT) for the evaluation of LAG-3 expression in primary and/or metastatic tumors, compared ...
Detailed Description
Participants with cancer underwent 68Ga-DOTA-hLAG-3 PET/CT for an initial assessment. Tumor uptake was quantified by the maximum standard uptake value (SUVmax) and mean SUV (SUVmean). In addition, the...
Eligibility Criteria
Inclusion
- (i) adult patients (aged 18 years or order);
- (ii) patients with newly diagnosed or previously treated malignant tumors (supporting evidence may include magnetic resonance imaging (MRI), CT, tumor markers and pathology report);
- (iii) patients who had scheduled 68Ga-NK224 PET/CT scans;
- (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
Exclusion
- (i) patients with non-malignant lesions;
- (ii) patients with pregnancy;
- (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Key Trial Info
Start Date :
October 10 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 13 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05346276
Start Date
October 10 2022
End Date
December 13 2024
Last Update
August 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First affiliated hospital of xiamen university
Xiamen, Fujian, China, 361000